The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Global distribution and prevalence of hepatitis C virus genotypes
Open accessAbstract
Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence. This poses a challenge to the improved development of vaccines and pan‐genotypic treatments, which require the consideration of global trends in HCV genotype prevalence. Here we provide the first comprehensive survey of these trends. To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project. We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information. We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population. We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one‐third of which are in East Asia. Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%. While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower‐income countries. Conclusion: Although genotype 1 is most common worldwide, nongenotype 1 HCV cases—which are less well served by advances in vaccine and drug development—still comprise over half of all HCV cases. Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments. Genotype surveillance data are needed from many countries to improve estimates of unmet need. (H epatology 2015;61:77–87)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Mathematical Theory of Communication
Shannon, C. E. (1948) · Bell System Technical Journal · doi:10.1002/j.1538-7305.1948.tb01338.x · Cited by 88,486
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Self-citationTelaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, S. A., Rice, C. M., Stapleton, J. T., & Simmonds, P. (2014) · Hepatology · doi:10.1002/hep.26744 · Cited by 1,353
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
Frank, C., Mohamed, M. K., Strickland, G. T., Lavanchy, D., Arthur, R. R., Magder, L. S., Khoby, T. E., Abdel-Wahab, Y., Ohn, E. S. A., Anwar, W., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06527-7 · Cited by 1,131
GBD 2010: design, definitions, and metrics
Murray, C. J., Ezzati, M., Flaxman, A. D., Lim, S., Lozano, R., Michaud, C., Naghavi, M., Salomon, J. A., Shibuya, K., Vos, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61899-6 · Cited by 1,103
Self-citationSofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
A proposed system for the nomenclature of hepatitis C viral genotypes
Simmonds, P., Alberti, A., Alter, H. J., Bonino, F., Bradley, D. W., Brechot, C., Brouwer, J. T., Chan, S.-W., Chayama, K., Chen, D.-S., et al. (1994) · Hepatology · doi:10.1002/hep.1840190538 · Cited by 1,023
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 910
(2010) · Clinical Infectious Diseases · doi:10.1086/652283 · Cited by 594
Lawitz, E., Poordad, F. F., Pang, P. S., Hyland, R. H., Ding, X., Mo, H., Symonds, W. T., McHutchison, J. G., & Membreno, F. E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62121-2 · Cited by 547
The changing epidemiology of hepatitis C virus infection in Europe
Esteban, J. I., Sauleda, S., & Quer, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.033 · Cited by 481
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T., & Kumar, R. (2013) · Hepatology · doi:10.1002/hep.26218 · Cited by 474
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., Townsend, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003155 · Cited by 405
Self-citationMurphy, D. G., Willems, B., Deschênes, M., Hilzenrat, N., Mousseau, R., & Sabbah, S. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02366-06 · Cited by 292
The origin of hepatitis C virus genotypes.
Smith, D. B., Yap, P. L., Simmonds, P., Lawlor, E., Power, J., Pathirana, S., & Davidson, F. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-2-321 · Cited by 284
2000 Fleming Lecture. The origin and evolution of hepatitis viruses in humans
Simmonds, P. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-4-693 · Cited by 219
Genetic History of Hepatitis C Virus in East Asia
Pybus, O. G., Barnes, E., Taggart, R., Lemey, P., Markov, P. V., Rasachak, B., Syhavong, B., Phetsouvanah, R., Sheridan, I., Humphreys, I. S., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01501-08 · Cited by 211
Self-citationThe Global Spread of Hepatitis C Virus 1a and 1b: A Phylodynamic and Phylogeographic Analysis
Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S. Y. W., Shapiro, B., Pybus, O. G., Allain, J.-P., & Hatzakis, A. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000198 · Cited by 196
Self-citationThe hepatitis C virus epidemic among injecting drug users
Pybus, O. G., Cochrane, A., Holmes, E. C., & Simmonds, P. (2005) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2004.08.001 · Cited by 162
Self-citationThe global health burden of hepatitis C virus infection
Negro, F., & Alberti, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02537.x · Cited by 145
Viral hepatitis and the G lobal B urden of D isease: a need to regroup
Cooke, G., Lemoine, M., Thursz, M. R., Gore, C., Swan, T., Kamarulzaman, A., du Cros, P., & Ford, N. P. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12123 · Cited by 122
Self-citationSequence diversity of hepatitis C virus: Implications for immune control and therapy
Timm, J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i36.4808 · Cited by 105
de Bruijne, J., Schinkel, J., Prins, M., Koekkoek, S. M., Aronson, S. J., van Ballegooijen, M., Reesink, H. W., Molenkamp, R., & van de Laar, T. J. W. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01146-09 · Cited by 85
Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS
Ford, N. P., Singh, K., Cooke, G., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis227 · Cited by 83
Self-citationInvestigating the endemic transmission of the hepatitis C virus
Pybus, O. G., Markov, P. V., Wu, A., & Tatem, A. J. (2007) · International Journal for Parasitology · doi:10.1016/j.ijpara.2007.04.009 · Cited by 71
Self-citationMarkov, P. V., van de Laar, T. J. W., Thomas, X. V., Aronson, S. J., Weegink, C. J., van den Berk, G. E. L., Prins, M., Pybus, O. G., & Schinkel, J. (2012) · Journal of Virology · doi:10.1128/jvi.06910-11 · Cited by 65
Self-citationEver closer to a prophylactic vaccine for HCV
Swadling, L., Klenerman, P., & Barnes, E. J. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.791277 · Cited by 60
Self-citation
Cited by
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M.-H., Negro, F., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30181-9 · Cited by 2,006
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C.-L., Chan, H. L. Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512610 · Cited by 1,106
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., & Cacciapuoti, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7824 · Cited by 864
Metadata
- Authors
- Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E.
- Venue
- Hepatology
- Published
- 2014-07-28
- Volume
- 61
- Issue
- 1
- Pages
- 77-87
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2133036275
- Cited by
- 1,589
- References
- 32
- FWCI
- 102.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.